Published in Emerg Infect Dis on August 01, 2006
Immune serum produced by DNA vaccination protects hamsters against lethal respiratory challenge with Andes virus. J Virol (2007) 1.27
Treatment of hantavirus pulmonary syndrome. Antiviral Res (2007) 1.21
DNA vaccine-generated duck polyclonal antibodies as a postexposure prophylactic to prevent hantavirus pulmonary syndrome (HPS). PLoS One (2012) 1.18
T cells are not required for pathogenesis in the Syrian hamster model of hantavirus pulmonary syndrome. J Virol (2011) 1.10
The Syrian hamster model of hantavirus pulmonary syndrome. Antiviral Res (2012) 1.10
Highly differentiated, resting gn-specific memory CD8+ T cells persist years after infection by andes hantavirus. PLoS Pathog (2010) 1.08
Person-to-person household and nosocomial transmission of andes hantavirus, Southern Chile, 2011. Emerg Infect Dis (2014) 0.97
Pathophysiology of hantavirus pulmonary syndrome in rhesus macaques. Proc Natl Acad Sci U S A (2014) 0.90
Effects of mefloquine use on Plasmodium vivax multidrug resistance. Emerg Infect Dis (2014) 0.86
Hantavirus pulmonary syndrome in Santa Cruz, Bolivia: outbreak investigation and antibody prevalence study. PLoS Negl Trop Dis (2012) 0.83
Phage display selection of cyclic peptides that inhibit Andes virus infection. J Virol (2009) 0.81
Molecular method for the detection of Andes hantavirus infection: validation for clinical diagnostics. Diagn Microbiol Infect Dis (2015) 0.75
Hantaviruses: a global disease problem. Emerg Infect Dis (1997) 9.67
Hantavirus pulmonary syndrome: a clinical description of 17 patients with a newly recognized disease. The Hantavirus Study Group. N Engl J Med (1994) 7.61
Hantavirus pulmonary syndrome outbreak in Argentina: molecular evidence for person-to-person transmission of Andes virus. Virology (1998) 2.71
An unusual hantavirus outbreak in southern Argentina: person-to-person transmission? Hantavirus Pulmonary Syndrome Study Group for Patagonia. Emerg Infect Dis (1997) 2.19
Placebo-controlled, double-blind trial of intravenous ribavirin for the treatment of hantavirus cardiopulmonary syndrome in North America. Clin Infect Dis (2004) 2.00
The incubation period of hantavirus pulmonary syndrome. Am J Trop Med Hyg (2000) 1.81
Shedding and intracage transmission of Sin Nombre hantavirus in the deer mouse (Peromyscus maniculatus) model. J Virol (2002) 1.62
Cardiopulmonary manifestations of hantavirus pulmonary syndrome. Crit Care Med (1996) 1.47
Hantavirus pulmonary syndrome in Latin America. Curr Opin Infect Dis (2004) 1.20
Hemorrhagic fever: a study of 300 cases. Medicine (Baltimore) (1954) 1.10
Peridomestic small mammals associated with confirmed cases of human hantavirus disease in southcentral Chile. Am J Trop Med Hyg (2004) 1.05
Three-week incubation period for hantavirus infection. Pediatr Infect Dis J (2004) 0.96
Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med (2004) 5.04
Strengthening health information systems to address health equity challenges. Bull World Health Organ (2005) 3.46
Prospective evaluation of household contacts of persons with hantavirus cardiopulmonary syndrome in chile. J Infect Dis (2007) 1.97
[Utility of real time polymerase chain reaction in the diagnosis of respiratory syncytial virus infection among adult patients]. Rev Chilena Infectol (2007) 1.40
[Analysis of a clinical ethics consultation experience in intensive care]. Rev Med Chil (2010) 1.39
Treatment of hantavirus pulmonary syndrome. Antiviral Res (2007) 1.21
Knee chondral lesions: incidence and correlation between arthroscopic and magnetic resonance findings. Arthroscopy (2007) 1.18
Alcohol absorption modification after a laparoscopic sleeve gastrectomy due to obesity. Obes Surg (2010) 1.09
Highly differentiated, resting gn-specific memory CD8+ T cells persist years after infection by andes hantavirus. PLoS Pathog (2010) 1.08
Peridomestic small mammals associated with confirmed cases of human hantavirus disease in southcentral Chile. Am J Trop Med Hyg (2004) 1.05
Gentamicin and tetracyclines for the treatment of human plague: review of 75 cases in new Mexico, 1985-1999. Clin Infect Dis (2004) 1.00
Person-to-person household and nosocomial transmission of andes hantavirus, Southern Chile, 2011. Emerg Infect Dis (2014) 0.97
Andes virus antigens are shed in urine of patients with acute hantavirus cardiopulmonary syndrome. J Virol (2009) 0.94
High-dose intravenous methylprednisolone for hantavirus cardiopulmonary syndrome in Chile: a double-blind, randomized controlled clinical trial. Clin Infect Dis (2013) 0.92
Fatal hemorrhagic pneumonia caused by human metapneumovirus in an immunocompetent child. Pediatr Int (2008) 0.90
Dengue-1 virus isolation during first dengue fever outbreak on Easter Island, Chile. Emerg Infect Dis (2003) 0.87
[Immunogenicity and reactogenicity of a reduced antigen content diphtheria, tetanus and acellular pertussis vaccine dTpa) in 10 to 11 years old children and in adults]. Rev Med Chil (2002) 0.86
Exclusion criteria for intravenous thrombolysis in stroke mimics: an observational study. J Stroke Cerebrovasc Dis (2012) 0.86
A non-randomized multicentre trial of human immune plasma for treatment of hantavirus cardiopulmonary syndrome caused by Andes virus. Antivir Ther (2014) 0.84
[Characteristics and factors associated with mortality in patients receiving mechanical ventilation: first Chilean multicenter study]. Rev Med Chil (2008) 0.83
Case report: T-cell responses during clearance of Andes virus from blood cells 2 months after severe hantavirus cardiopulmonary syndrome. J Med Virol (2008) 0.81
Socioeconomic and cardiovascular variables explaining regional variations in stroke mortality in Chile: an ecological study. Neuroepidemiology (2011) 0.81
[Income inequality and self rated health: an analysis from a contextual perspective in Chile]. Rev Med Chil (2003) 0.80
[Gender inequity in the access to health care in Chile]. Rev Med Chil (2003) 0.80
Andes virus infections in the rodent reservoir and in humans vary across contrasting landscapes in Chile. Infect Genet Evol (2009) 0.79
Steroid withdrawal in pediatric kidney transplant allows better growth, lipids and body composition: a randomized controlled trial. Horm Res Paediatr (2013) 0.79
Ventilatory inefficiency as a limiting factor for exercise in patients with COPD. Respir Care (2011) 0.79
The short peritoneal equilibration test in pediatric peritoneal dialysis. Pediatr Nephrol (2010) 0.79
Respiratory syncytial virus detection in cells and clinical samples by using three new monoclonal antibodies. J Med Virol (2013) 0.78
[Influenza-A as etiology of fever and respiratory insufficiency in adults hospitalized during an outbreak in Chile]. Rev Med Chil (2004) 0.78
Growth in Chilean infants with chromosome 22q11 microdeletion syndrome. Am J Med Genet A (2012) 0.78
[Consensus: Rational approach towards the patient with cancer, fever and neutropenia]. Rev Chilena Infectol (2005) 0.78
[Source of infection in young infants hospitalized with Bordetella pertussis]. Rev Med Chil (2011) 0.78
Continuous EPO receptor activator therapy of anemia in children under peritoneal dialysis. Pediatr Nephrol (2011) 0.78
The mini-PET in pediatric peritoneal dialysis: a useful tool to predict volume overload? Pediatr Nephrol (2013) 0.77
[Experience with capsule endoscopy diagnostic tool for the small intestine]. Rev Med Chil (2010) 0.76
Hantavirus pulmonary syndrome, Southern Chile, 1995-2012. Emerg Infect Dis (2015) 0.76
A rapid method for infectivity titration of Andes hantavirus using flow cytometry. J Virol Methods (2013) 0.76
XV-2c and KM.19 haplotype analysis in Chilean patients with cystic fibrosis and unknown CFTR gene mutations. Biol Res (2007) 0.76
Incidence of subarachnoid haemorrhage in the Aconcagua Valley, Chile: a community-based, prospective surveillance project. J Neurol Neurosurg Psychiatry (2010) 0.76
Rates of hospital-acquired influenza due to the pandemic H1N1 virus in 2009, compared with seasonal influenza. Infect Control Hosp Epidemiol (2011) 0.76
HIV-1 tropism: a comparison between RNA and proviral DNA in routine clinical samples from Chilean patients. Virol J (2013) 0.75
[Not Available]. Rev Med Chil (2016) 0.75
Case-Control Study of Risk Factors for Meningococcal Disease in Chile. Emerg Infect Dis (2017) 0.75
[Importance of images and etiological diagnosis in the immunocompromised patient with central nervous system envolvement. Part II]. Rev Chilena Infectol (2011) 0.75
[Nosocomial infections after cardiac surgery in infants and children with congenital heart disease]. Rev Chilena Infectol (2014) 0.75
Laser Ablation of Silver in Liquid Organic Monomer: Influence of Experimental Parameters on the Synthesized Silver Nanoparticles/Graphite Colloids. J Phys Chem B (2017) 0.75
[Early detection of cytomegalovirus infection in allogeneic hematopoietic stem cell transplant patients by real time-quantitative PCR]. Rev Chilena Infectol (2014) 0.75
[Clinical features and prognostic factors of meningococcal disease: a case series study in Chile during the 2012-2013 outbreak]. Rev Chilena Infectol (2015) 0.75
[Analysis of the new health module of the National Socioeconomic Characterization Survey 2000]. Rev Med Chil (2004) 0.75
[Reducing the incidence of ventilator-associated pneumonia following heart surgery: 13-year experience of epidemiologic surveillance in a teaching hospital]. Rev Chilena Infectol (2013) 0.75
[Parechovirus as etiologic agent of meningitis and/or sepsis like illness in infants]. Rev Chilena Infectol (2016) 0.75
[Accuracy and diagnostic utility of IgM in Bartonella henselae infections]. Rev Chilena Infectol (2013) 0.75
[Search of amantadine-resistance in influenza A strains isolated in Santiago, Chile, 2001-2002]. Rev Chilena Infectol (2005) 0.75